TITLE

HCSD: the human cancer secretome database

AUTHOR(S)
Feizi, Amir; Banaei-Esfahani, Amir; Nielsen, Jens
PUB. DATE
January 2015
SOURCE
Database: The Journal of Biological Databases & Curation;2015, Vol. 2015, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The human cancer secretome database (HCSD) is a comprehensive database for human cancer secretome data. The cancer secretome describes proteins secreted by cancer cells and structuring information about the cancer secretome will enable further analysis of how this is related with tumor biology. The secreted proteins from cancer cells are believed to play a deterministic role in cancer progression and therefore may be the key to find novel therapeutic targets and biomarkers for many cancers. Consequently, huge data on cancer secretome have been generated in recent years and the lack of a coherent database is limiting the ability to query the increasing community knowledge. We therefore developed the Human Cancer Secretome Database (HCSD) to fulfil this gap. HCSD contains >80 000 measurements for about 7000 nonredundant human proteins collected from up to 35 high-throughput studies on 17 cancer types. It has a simple and user friendly query system for basic and advanced search based on gene name, cancer type and data type as the three main query options. The results are visualized in an explicit and interactive manner. An example of a result page includes annotations, cross references, cancer secretome data and secretory features for each identified protein. Database URL: www.cancersecretome.org.
ACCESSION #
108777143

 

Related Articles

  • Prostate news.  // Prostate Cancer & Prostatic Diseases;2008, Vol. 11 Issue 4, p312 

    The article highlights the findings of various research on prostate cancer and prostatic diseases. One study found that prostate-specific antigen is the best biomarker for monitoring prostate cancer progression. Findings of another study suggests that taller men are at increased risk for...

  • MicroRNA-195-5p, a new regulator of Fra-1, suppresses the migration and invasion of prostate cancer cells. Jian Wu; Alin Ji; Xiao Wang; Yi Zhu; Yasai Yu; Yiwei Lin; Yunfu Liu; Shiqi Li; Zhen Liang; Xin Xu; Xiangyi Zheng; Liping Xie // Journal of Translational Medicine;9/6/2015, Vol. 13 Issue 1, p1 

    Background: An increasing number of studies have demonstrated that deregulation of microRNAs (miRNAs) was a common event in tumor tissues and miRNAs would be treated as ideal tumor biomarkers or therapeutic targets. miR-195-5p (termed as miR-195 for briefly in the following part) was suggested...

  • Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Crea, Francesco; Hurt, Elaine M.; Mathews, Lesley A.; Cabarcas, Stephanie M.; Lei Sun; Marquez, Victor E.; Danesi, Romano; Farrar, William L. // Molecular Cancer;2011, Vol. 10 Issue 1, p40 

    Background: Polycomb repressive complex 2 (PRC2) mediates gene silencing through histone H3K27 methylation. PRC2 components are over-expressed in metastatic prostate cancer (PC), and are required for cancer stem cell (CSC) self-renewal. 3-Dezaneplanocin-A (DZNeP) is an inhibitor of PRC2 with...

  • The Angiogenic Activity of Ascites in the Course of Ovarian Cancer as a Marker of Disease Progression. Gawrychowski, Krzysztof; Szewczyk, Grzegorz; Różewska, Ewa Skopińska; Malecki, Maciej; Barcz, Ewa; Kamiński, Paweł; Miedzińska-Maciejewska, Magdalena; Śmiertka, Wacław; Szukiewicz, Dariusz; Skopiński, Piotr // Disease Markers;2014, p1 

    Ovarian cancer cells are able to create invasive implants in the peritoneum and their growth is directly associated with the angiogenetic potential. This effect is probably stimulated by vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8), which are both found in ascites. The aim...

  • Sequential maximum androgen blockade (MAB) in minimally symptomatic prostate cancer progressing after initial MAB: two case reports. Hingorani, Mohan; Dixit, Sanjay; Bashir, Fahim; Butt, Mohammad; Hawkyard, Simon; Khafagy, Richard; Robertson, Andrew // Cancer Biology & Medicine;Dec2014, Vol. 11 Issue 4, p277 

    The management of castrate-resistant prostate cancer progressing after maximum androgen blockade (MAB) has evolved in the last decade with the development of several novel therapeutic options. However, the initial therapeutic strategy in these patients usually involves withdrawal of...

  • Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. Burchell, Joy // Current Medical Literature: Breast Cancer;2012, Vol. 24 Issue 4, p146 

    The article discusses a research paper on the marker, GD2, and its role in identifying breast cancer cells. It references a study by V. L. Battula et al. published in a 2012 issue of the "Journal of Clinical Investigation". It is concluded that GD2 can identify breast cancer SCs and play a role...

  • Cancer Testis Antigen Expression in Breast cancer Tissues and Cell Lines. Amoli, S. Yousef; Kokabee, L.; Majidzadeh-A, K.; Kordafshari, A. R.; Rahimi, H.; Esmaeili, R.; Izadi, P.; Noruzinia, M.; Maryami, F.; Karimipour, M. // Advances in Bioresearch;Jan2015, Vol. 6 Issue 1, p79 

    Cancer/Testis genes (CT-genes) are a gene family which only express in testis tissue but not in somatic tissues. Although some of them are randomly expressed in some types of cancers. The aim of this study was to analyze the expression of several cancer-testis genes in breast cancer and cancer...

  • For IDH1, Change in Mechanism Opens Up Targeting Possibilities. Breindl, Anette // BioWorld Today;11/24/2009, Vol. 20 Issue 227, p1 

    The article discusses research being done on how the isocitrate dehydrogenase 1 (IDH1) enzyme contributes to cancer. It references a study by David Schenkein et al published in the November 22, 2009 advance online edition of "Nature." Results revealed that a gain in the enzyme's biochemical...

  • Expression Levels of Transcribed Ultraconserved Regions uc.73 and uc.388 Are Altered in Colorectal Cancer. Sana, J.; Hankeova, S.; Svoboda, M.; Kiss, I.; Vyzula, R.; Slaby, O. // Oncology;Mar2012, Vol. 82 Issue 2, p114 

    Objectives: The development of colorectal cancer (CRC) is characterized by multiple genetic alterations. Transcribed ultraconserved regions (T-UCRs) are a subset of 481 sequenc es longer than 200 bp, which are absolutely conserved between orthologous regions of human, rat and mouse genomes, and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics